IL23A and basal cell carcinoma: The risk of malignancies was also compared with biologic-naive patients in which IL-23 inhibitors showed a significantly smaller risk of colorectal cancer (1.1% vs. 0.3%), basal cell carcinoma (3.4% vs. 1.5%), and Cutaneous squamous cell carcinoma (0.6% vs. 0.2%) during 5-year follow-up.